Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity.

ABSTRACT: The identification of molecular biomarkers in CSF from individuals affected by Huntington disease may help improve predictions of disease onset, better define disease progression and could facilitate the evaluation of potential therapies. The primary objective of our study was to investigate novel CSF protein candidates and replicate previously reported protein biomarker changes in CSF from Huntington disease mutation carriers and healthy controls. Our secondary objective was to compare the discriminatory potential of individual protein analytes and combinations of CSF protein markers for stratifying individuals based on the severity of Huntington disease. We conducted a hypothesis-driven analysis of 26 pre-specified protein analytes in CSF from 16 manifest Huntington disease subjects, eig

SUBMITTER: Caron NS 

PROVIDER: S-EPMC9746690 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature